The use of Haemostatic Agents does not impact the rate of hemorrhagic complications in patients undergoing partial nephrectomy for renal masses

Yasmin Abu-Ghanem¹,², Zohar Dotan¹,², Issac Kaver¹,², Dorit E. Zilberman¹,² & Jacob Ramon¹,²

Hemostatic agents (HAs) have gained increasing popularity as interventions to improve perioperative haemostasis and diminish the need for allogeneic red cell transfusion (PBT) despite a paucity of data supporting the practice. The aim of the current study is to examine the efficacy of HAs in reducing the rate of hemorrhagic complications during partial nephrectomy (PN). Data on 657 patients, who underwent elective PN between 2004–2013, were analyzed. The impact of HAs and SURGICEL was evaluated by comparing four sequential groups of patients: Group1 = Sutures alone, Group2 = sutures and HA, Group3 = sutures and SURGICEL, Group4 = both HA and SURGICEL. Complications included post-operative urinary leak (UL), PBT rate, delayed bleeding and post-operative renal failure. Results showed that the use of HAs did not engender a statistically significant difference in overall complications rate. Specifically, the addition of HAs did not reduce the rate of PBT, delayed bleeding or UL. Further analysis revealed that patients who received SURGICEL had significantly higher PBT rate and higher prevalence of UL cases. Addition of HAs to SURGICEL had no effect on the rate of these complications. In the current study, the use of HAs during open and laparoscopic PN did not reduce the rate of negative outcomes. Adequate suture renorrhaphy may be sufficient to prevent hemorrhagic complications.

In recent years, partial nephrectomy (PN), and specifically laparoscopic PN (LPN) has become the standard of care in the management of selected renal lesions¹. Initially, LPN was proffered only in the case of a small, peripheral, exophytic tumor. However, with increasing experience, the application of LPN has extended to tumors invading more deeply into the renal parenchyma up to the collecting system or renal sinus²,³. Nevertheless, as laparoscopic surgeons approach more difficult tumors, the complexity of tumors requiring Open PN (OPN) is even further magnified. In both approaches, the excision of such deeply infiltrating tumors routinely necessitates division of major intrarenal vessels and precise entry into the collecting system to ensure an adequate margin of resection. Such resections are therefore associated with significant risks of bleeding and urinary leak³.

Despite the relatively low incidences of hemorrhagic complications requiring transfusion after PN, it remains one of the most serious complications⁴. With many reports suggesting that allogeneic blood transfusion is associated with an adverse outcome⁵–⁷, several attempts have been made to reduce the risk of bleeding. In the past decades, a wide variety of haemostatic agents (HAs) has been developed as surgical tools, in order to reduce the rate of such complications. Different tissue adhesives (also called glues) have been used to assist in haemostasis and collecting system closure during open and laparoscopic PN⁸–¹². Yet, despite the growing clinical application of HA during PN, there is little data regarding their cost-effectiveness in preventing major complications¹³. In this study, we present an analysis of the effectiveness of using HAs and glues in laparoscopic and open PN.

¹Dept. of Urology, Sheba Medical Center, Israel. ²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israe. Correspondence and requests for materials should be addressed to Y.A.-G. (email: ag.yasmin@gmail.com)
Patients and Methods
A total of 657 consecutive patients underwent PN at our institution between 2004 and 2013. All operations were performed in the same surgical environment (four surgeons operating in one medical center). Patient demographics and surgical details were collected retrospectively, following an approval given by the Sheba Medical Center Institutional Review Board (IRB)/Ethics (Helsinki) Committee, in accordance with relevant guidelines and regulations. The need for informed consent was waived by our IRB. All patients were considered for a comparative study, and four groups were defined on the basis of the method of haemostasis used during the procedure. Group 1 = renorrhaphy was completed using sutures alone in 147 patients (22.4%); Group 2 = both sutures and HA were used in 26 patients (3.9%); group 3 = sutures and SURGICEL (Ethicon, Somerville, NJ, USA), without HA in 183 (27.8%) patients; and group 4 = sutures, HA and SURGICEL in 301 (45.8%) patients.

Altogether, 327 patients received HA (with or without SURGICEL). Of those, 290 (88.6%) received cryoprecipitate, prepared from a single allogeneic donor, combined with commercially prepared thrombin. The remaining patients received commercial sealants (bovine serum albumin–based adhesive, BioGlue; Kennesaw, GA, USA). In all cases, HA were used by covering the renal injury immediately after performing sutured renorrhaphy. Patient demographics and operative details were collected retrospectively. Clinicopathologic variables recorded included: age, gender, height, weight and Body Mass Index (BMI), preoperative hemoglobin and creatinine levels, receipt of perioperative blood transfusion (PBT) and number of units transfused. Pathology related variables included: tumor location, multifocal mass, central or hilar tumor, mass size, as well as tumor pathology- malignant tumor (i.e, Renal Cell Carcinoma (RCC), malignancies other than RCC were excluded) and benign lesion (AML, Oncocytoma, benign cyst). Other pathological features as Adrenal Invasion and Perinephric Fat Extension were documented in less than 2% of the patients and therefore were not included.

Operative variables included the type of operation (open or laparoscopic), renal ischemia (clamping of the renal artery, Yes/No) and ischemia time data. Complications included post-operative urinary leak, delayed bleeding (hematuria or flank hematoma), post-operative renal failure, development of pseudoaneurysm and PBT administration. PBT was defined as transfusion of allogeneic red blood on the day of operation or within the postoperative hospitalization. Post-operative renal failure was defined by any increase in serum creatinine of ≥1.5-fold from the pre-operative baseline.

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS, Version 18.0, Chicago, IL, USA). One-way ANOVA was used for analysis of continuous variables and the chi-square test was used for analysis of categorical variables. A P-value of less than 0.05 was considered statistically significant.

Result
Six hundred and fifty seven patients underwent partial nephrectomy during the study period. Table 1 lists baseline demographics for the entire study cohort. Of the 657 patients, 87 patients (13.3%) received perioperative blood transfusion. The median number of RBC units was 2. Urinary leak was observed in 17 patients (2.6%).

Sutures alone vs Sutures and HA. The demographic data of the two groups were comparable in terms of age, gender, Body Mass Index (BMI), kidney side, tumor location along the kidney (i.e, upper or lower pole) and tumor size. Both groups had a similar number of patients with central and hilar tumors, rate of malignant tumors (RCC) and similar proportion of patients undergoing renal artery clamping. The use of a HA did not show a statistically significant difference in warm ischemia time (14.5 vs 19.7 minutes, p = X NS). Furthermore, overall complications did not differ between groups. Specifically, addition of HA did not reduce the rate of PBT (4.1% vs 7.7%, p = NS), delayed bleeding or flank hematomas (2 patients in HAs group and 5 in the parallel group, p = NS). No case of pseudoaneurysm was recorded in any of the patients receiving HAs in comparison to only one case in the parallel group (p = NS). No differences were observed in the rate of post-operative renal failure (Table 2).

Sutures alone vs Sutures and SURGICEL. Univariate analysis revealed that the two groups were comparable in age, gender, BMI, preoperative HB levels and rate of RCC. However, patients who received SURGICEL had significantly larger tumors in comparison to sutures alone (3.8 cm and 3.08 cm respectively, p = 0.03), higher rate of central renal lesions (43.2% vs 23.8%, p < 0.001) and lower rate of renal vascular clamping (69.5% vs 85.5%, p = 0.004). The majority of patients in the SURGICEL group were operated upon by an open approach (89.6% vs 36.7%, p = 0.001). In regards to complications, analysis of these sub-groups revealed that patients in the SURGICEL group had significantly higher PBT rate (p < 0.001) and higher prevalence of urinary leak cases (p < 0.05). No differences were observed in regards to delayed bleeding (including hematuria or flank hematoma). Notably, a higher incidence rate of pseudoaneurysm events was recorded in the SURGICEL group in comparison to sutures alone (3.3% vs 0.7% respectively, p = NS). No differences were observed in the rate of post-operative renal failure (Table 2).

Sutures, HA and SURGICEL vs Sutures and SURGICEL. The two groups were comparable in age, gender, BMI, preoperative HB levels and rate of RCC. The group of patients who received HA in addition to SURGICEL had significantly smaller tumors in comparison to the ‘HA free’ patients (3.21 and 3.8 cm respectively, P = 0.001), lower prevalence of central renal lesions (P = 0.03) and higher rate of renal vascular clamping (P < 0.001). The majority of patients in this group were operated upon by a laparoscopic approach. The addition of HA to SURGICEL did not show a statistically significant difference in the rate of PBT (14.6% and 19.1%, P = NS), the prevalence of urinary leak (2.3% and 4.9%, P = NS) or the rate of delayed bleeding including the rate of hematuria, flank hematomas and pseudoaneurysms. Additionally, no differences were observed in the rate of post-operative renal failure (Table 3).

Analysis based on surgical approach (Open vs. Laparoscopic). In subgroup analysis of the laparoscopic approach alone, the two groups of patients were similar in all clinicopathological variables, including mass
size, prevalence of central tumors, tumor location and rate of RCC. The only different variable was rate of renal vascular clamping. The majority of patients who received both SURGICEL and HAs, had significantly higher rate of clamping in comparison to SURGICEL alone (88.6% vs 52.6%, \( P = 0.001 \)), yet no differences were observed in ischemia time. Comparison of the complication rate did not reveal any advantage to the addition of HA to SURGICEL in regards to PBT rate or post-operative bleeding. However, in the laparoscopic group, the addition of HA to SURGICEL decreased significantly the rate of leaks requiring stent insertion (\( P = 0.002 \)). Yet, no advantage to HAs in comparison to sutures alone in regards to hemorrhagic complications (including rate of PBT) or the rate of urinary leak was found (Table 4).

Similar results were observed when clinical features and outcomes were compared in patients operated upon by an open approach. Since the number of patients in the ‘Sutures and HA’ group that were operated by an open approach was too small (n = 5), this group was not compared to sutures alone (Table 5). Further analysis of the complication rate only in patients in which renal artery clamping was not performed revealed no advantage in the use of HA, both in comparison to sutures alone or sutures combined with SURGICEL.

| Variable                      | No. (%) |
|------------------------------|---------|
| Age (years) (median ± sd)     | 61.85 ± 12.6 |
| Gender                       |         |
| Male                         | 437 (66.5) |
| Female                       | 220 (33.5) |
| BMI                          | 27.1 ± 4.8 |
| Preoperative HB (g/dL)       | 13.6 ± 1.50 |
| Preoperative Serum Creatinine | 1.02 ± 0.37 |
| Central renal lesion         | 216 (32.9) |
| Mass location                |         |
| Upper Pole                   | 168 (25.6) |
| Middle aspect                | 120 (18.3) |
| Lower Pole                   | 206 (31.4) |
| Mixed                        | 163 (24.7) |
| Kidney side                  |         |
| Left Kidney                  | 329 (50.2) |
| Right Kidney                 | 326 (49.8) |
| Tumor size                   | 3.0 ± 1.49 |
| \( \leq 4 \text{ cm} \)     | 517 (78.7) |
| \( >4 \text{ cm} \)         | 140 (21.3) |
| Pathology                    |         |
| Malignant (RCC)              | 493 (75) |
| Non-malignant*               | 164 (25) |
| Operative method             |         |
| Open                         | 269 (40.9) |
| Laparoscopic                 | 388 (59.1) |
| Renal vascular clamping      | 519 (78.9) |
| Ischemia time                | 20.0 ± 8.6 |
| Renorrhaphy                  |         |
| Sutures alone                | 147     |
| Sutures and HA               | 25      |
| Sutures and SURGICEL         | 183     |
| Suture, HA and SURGICEL      | 301     |
| PBT                          | 87 (13.3) |
| Leak                         | 17 (2.6)  |
| Delayed bleeding             |         |
| Hematuria                    | 10 (1.5)  |
| Flank hematoma               | 6 (0.91)  |
| Pseudoaneurysm               | 16 (2.4)  |
| Renal Failure                | 12 (1.8)  |
| DVT/PE                       | 5 (0.76)  |

Table 1. Clinicopathologic demographics of 657 patients included in the study. Values in parentheses are percentages; Abbreviations: PBT = Perioperative blood transfusion; BMI = Body Mass Index; HB = Hemoglobin; RCC = Renal Cell Carcinoma; HA = Hemostatic agents; DVT = deep vein thrombosis; PE = pulmonary embolism. *Angiomyolipoma (AML), Oncocytoma, simple cyst.
Cryoprecipitate Thrombin vs commercially prepared sealants. This Study included 263 patients treated with Cryoprecipitate thrombin and SURGICEL whereas 38 were treated with both commercial HA and SURGICEL. No differences were found in regards to PBT rate or incidence of urinary leak between the 2 groups. Patients were further divided based on the type of HA used. Eighteen patients were treated with Cryoprecipitate thrombin alone and 8 with commercial sealants. No differences were observed in regards to PBT rate or incidence of urinary leak between the 2 groups.

Discussion

The use of tissue sealants and glues as HAs while operating or in the operation of PN has gained popularity. However, despite their growing clinical application, their significance in preventing hemorrhage and urinary leak is not evidence based and the decision of using it depends mainly on individual experience. In 2007, Breda et al.13, 15, 16

| Variable                  | Sutures alone (n = 147) | Sutures and HA (n = 26) | P value  | Sutures and SURGICEL (n= 183) | P value  |
|---------------------------|-------------------------|-------------------------|----------|--------------------------------|----------|
| Age (years)               | 58.7 ± 13.5             | 64.3 ± 9.7              | 0.112    | 61.6 ± 13.5                    | 0.887    |
| Gender                    |                         |                         |          |                                |          |
| Male                      | 97 (66)                 | 19 (73.1)               | 0.761    | 117 (63.9)                     | 0.698    |
| Female                    | 50 (34)                 | 7 (26.9)                |          | 66 (36.1)                      |          |
| BMI                       | 26.1 ± 5.6              | 25.9 ± 4.02             | 0.164    | 27.7 ± 4.7                     | 0.612    |
| Mass location             |                         |                         |          |                                |          |
| Upper Pole                | 42 (28.6)               | 3 (11.5)                | 0.071    | 53 (29)                        | 0.135    |
| Middle aspect             | 22 (15)                 | 5 (19.2)                |          | 38 (20.8)                      |          |
| Lower Pole                | 38 (25.9)               | 12 (46.2)               |          | 55 (30.1)                      |          |
| Mixed                     | 45 (30.6)               | 6 (23.1)                |          | 37 (20.2)                      |          |
| Multifocal mass           | 16 (10.9)               | 3 (11.5)                | 0.922    | 32 (17.5)                      | 0.091    |
| Kidney side               |                         |                         |          |                                |          |
| Left Kidney               | 71 (48.3)               | 16 (61.5)               | 0.213    | 87 (47.5)                      | 0.887    |
| Right Kidney              | 76 (51.7)               | 10 (38.5)               |          | 96 (52.5)                      |          |
| Central renal lesion      | 35 (23.8)               | 9 (34.6)                | 0.243    | 79 (43.2)                      | <0.001   |
| Hilar renal lesion        | 16 (10.9)               | 3 (11.5)                | 0.922    | 31 (16.9)                      | 0.118    |
| Mass size                 | 3.01 ± 1.43             | 2.47 ± 1.1              | 0.727    | 3.83 ± 1.62                    | 0.003    |
| < 4 cm                    | 135 (91.8)              | 24 (92.3)               |          | 117 (63.9)                     |          |
| > 4 cm                    | 12 (8.2)                | 2 (7.7)                 |          | 66 (36.1)                      |          |
| Pathology                 |                         |                         |          |                                |          |
| Malignant (RCC)           | 104 (70.7)              | 20 (76.9)               | 0.59     | 140 (76.5)                     | 0.61     |
| Non-malignant*            | 43 (29.3)               | 6 (23.1)                |          | 43 (23.5)                      |          |
| Operative method          |                         |                         |          |                                |          |
| Open                      | 54 (36.7)               | 5 (19.2)                | 0.083    | 164 (89.6)                     | <0.001   |
| Laparoscopic              | 93 (63.3)               | 21 (80.8)               |          | 19 (10.4)                      |          |
| Renal vascular clamping   |                         |                         |          |                                |          |
| Yes                       | 107 (72.8)              | 21 (80.8)               | 0.393    | 127 (69.4)                     | 0.004    |
| No                        | 40 (27.2)               | 5 (19.2)                |          | 56 (30.6)                      |          |
| Ischemia Time (min)       | 19.7 ± 10.9             | 14.5 ± 8.5              | 0.283    | 15.8 ± 10.6                    | 0.87     |
| Preoperative HB (g/dL)    | 13.6 ± 1.5              | 13.8 ± 1.1              | 0.09     | 13.5 ± 1.55                    | 0.899    |
| Discharge HB (g/dL)       | 11.4 ± 1.5              | 11.8 ± 1.5              | 0.845    | 11.45 ± 1.35                   | 0.261    |
| PBT                       | 6 (4.1)                 | 2 (7.7)                 | 0.419    | 35 (19.1)                      | <0.001   |
| Leak                      | 1 (0.7)                 | 0 (0)                   | 0.673    | 9 (4.9)                        | 0.026    |
| Delayed bleeding          |                         |                         |          |                                |          |
| Hematuria                 | 3 (2.04)                | 1 (3.8)                 | 0.576    | 2 (1.6)                        | 0.867    |
| Flank hematoma            | 0 (0)                   | 0 (0)                   | 0.773    | 1 (0.5)                        | NA       |
| Pseudoaneurysm            | 1 (0.7)                 | 0 (0)                   | NA       | 5 (2.7)                        | 0.836    |
| Renal Failure             | 3 (2.04)                | 0 (0)                   | NA       | 6 (3.3)                        | 0.718    |
| DVT/PE                    | 0 (0)                   | 1 (3.8)                 | NA       | 3 (0.55)                       | NA       |

Table 2. Univariate analysis - clinical, demographic, operative, and perioperative data of patients undergoing Partial Nephrectomy with only parenchymal suture vs: parenchymal suture with hemostatic agents and SURGICEL, suture with only HA and sutures with only SURGICEL. Values in parentheses are percentages; Abbreviations: PBT = Perioperative blood transfusion; BMI = Body Mass Index; HB = Hemoglobin; RCC = Renal Cell Carcinoma; HA = Hemostatic agents; DVT = deep vein thrombosis; PE = pulmonary embolism. *Angiomyolipoma (AML), Oncocytoma, simple cyst.
reported the results of a large multi-institutional survey, examining the usage patterns of HAs in LPN. The study included 18 centers from Europe and the United States in 1347 LPN cases. Breda and colleagues demonstrated, that up to 80% of urologists used the assistance of one or more HAs intraoperatively. Moreover, of the 18 centers, parenchymal suturing over a bolster of SURGICEL was consistently used by 16 centers. The investigators concluded that although there appears to be some advantage in the use of these agents, they should be limited to control minor bleeding in conjunction with other measurements, including parenchymal suturing over a bolster. However, despite these recommendations, it seems that the use of HAs is still vast, even though there is limited data supporting their effectiveness. In the current study we tried to examine the value of using HAs in PN. Following Breda et al., we further analyzed its value with and without the use of SURGICEL. In this study, the use of HAs did not improve or alter the rate of perioperative or post-operative bleeding as well as the rate of urinary leak when compared to sutures alone. When compared to SURGICEL (Table 3) despite the “advantages” in the tumor features (smaller tumors, less centrally located, laparoscopic approach) the addition of HA to the

| Variable                     | Suture, HA and SURGICEL (n = 301) | Sutures and SURGICEL (n = 183) | P value |
|------------------------------|----------------------------------|--------------------------------|---------|
| Age (years)                  | 61.5 ± 11.6                      | 61.6 ± 13.5                    | 0.079   |
| Gender                       |                                  |                                |         |
| Male                         | 204 (67.8)                       | 117 (63.9)                     | 0.386   |
| Female                       | 97 (32.2)                        | 66 (36.1)                      |         |
| BMI                          | 28.1 ± 4.8                       | 27.7 ± 4.7                     | 0.853   |
| Mass location                |                                  |                                |         |
| Upper Pole                   | 53 (29)                          | 70 (23.2)                      | 0.368   |
| Middle aspect                | 38 (20.8)                        | 55 (18.3)                      |         |
| Lower Pole                   | 55 (30)                          | 101 (33.5)                     |         |
| Mixed                        | 37 (20.2)                        | 75 (25)                        |         |
| Multifocal mass              | 14 (4.7)                         | 32 (17.5)                      | 0.123   |
| Kidney side                  |                                  |                                | 0.359   |
| Left Kidney                  | 156 (51.8)                       | 87 (47.5)                      |         |
| Right Kidney                 | 145 (48.2)                       | 96 (52.5)                      |         |
| Central renal lesion         | 101 (33.6)                       | 79 (43.2)                      | 0.034   |
| Hilar renal lesion           | 40 (13.3)                        | 31 (16.9)                      | 0.271   |
| Mass size                    | 3.21 ± 1.4                       | 3.8 ± 1.6                      | <0.001  |
| <4cm                         | 241 (80.1)                       | 117 (63.9)                     |         |
| >4cm                         | 60 (19.9)                        | 66 (36.1)                      |         |
| Pathology                    |                                  |                                |         |
| Malignant (RCC)              | 229 (76.1)                       | 140 (76.5)                     | 0.92    |
| Non-malignant*               | 72 (23.9)                        | 43 (23.5)                      |         |
| Operative method             |                                  |                                | <0.001  |
| Open                         | 46 (15.3)                        | 164 (89.6)                     |         |
| Laparoscopic                 | 255 (84.7)                       | 19 (10.4)                      |         |
| Renal vascular clamping      |                                  |                                | <0.001  |
| Yes                          | 269 (89.4)                       | 127 (69.4)                     |         |
| No                           | 32 (10.6)                        | 56 (30.6)                      |         |
| Ischemia Time (min)          | 22.5 ± 10.3                      | 14.8 ± 10.6                    | 0.950   |
| Preoperative HB (g/dL)       | 13.6 ± 1.5                       | 13.5 ± 1.55                    | 0.222   |
| Postoperative HB (g/dL)      | 11.86 ± 1.5                      | 11.45 ± 1.35                   | 0.473   |
| PBT                          | 44 (14.6)                        | 35 (19.1)                      | 0.193   |
| Leak                         | 7 (2.3)                          | 9 (4.9)                        | 0.122   |
| Delayed bleeding             |                                  |                                |         |
| Hematuria                    | 4 (1.3)                          | 2 (1.6)                        | 0.794   |
| Flank hematoma               | (1.3)                            | 1 (0.5)                        | 0.832   |
| Pseudoaneurysm               | 10 (3.3)                         | 5 (2.7)                        | 0.798   |
| Renal Failure                | 3 (1.0)                          | 6 (3.3)                        | 0.153   |
| DVT/PE                       | 2 (0.67)                         | 3 (0.55)                       | 0.462   |

Table 3. Univariate analysis - clinical, demographic, operative, and perioperative data of patients undergoing Partial Nephrectomy with only parenchymal suture, or parenchymal suture with SURGICEL and Hemostatic agents. Values in parentheses are percentages; Abbreviations: PBT = Perioperative blood transfusion; BMI = Body Mass Index; HB = Hemoglobin; RCC = Renal Cell Carcinoma; HA = Hemostatic agents; DVT = deep vein thrombosis; PE = pulmonary embolism. *Angiomyolipoma (AML), Oncocytoma, simple cyst.
SURGICEL did not reduce the rate of complications, including urinary leak or the need for PBT. Moreover, since vascular clamping was previously associated with decreased hemorrhagic complications, and specifically lower PBT rate\(^{12}\), we further analyzed the theoretical advantage of HA to sutures and SURGICEL in patients in which

| Variable                        | Suture, HA and SURGICEL (n = 255) | Sutures and SURGICEL (n = 19) | P value | Suture and HA (n = 21) | Sutures alone (n = 93) | P value |
|---------------------------------|-----------------------------------|-------------------------------|---------|------------------------|------------------------|---------|
| Age (years)                     | 62 ± 11.3                         | 61.9 ± 15.3                   | 0.347   | 63.1 ± 9.8             | 57.6 ± 13.4            | 0.229   |
| Central renal lesion            | 74 (29)                           | 2 (10.5)                      | 0.083   | 5 (23.8)               | 10 (10.8)              | 0.110   |
| Mass size                       | 3.04 ± 1.3                        | 3.03 ± 1.6                    | 0.127   | 2.43 ± 1.2             | 2.7 ± 0.96             | 0.333   |
| <4cm                            | 218 (85.5)                        | 15 (78.9)                     | 0.19    | 19 (90.5)              | 95.7                   |         |
| >4cm                            | 37 (14.5)                         | 4 (21.1)                      |         | 2 (9.5)               | 4 (4.3)                |         |

Pathology

| Pathology                      | Suture, HA and SURGICEL (n = 255) | Sutures and SURGICEL (n = 19) | P value | Suture and HA (n = 21) | Sutures alone (n = 93) | P value |
|--------------------------------|-----------------------------------|-------------------------------|---------|------------------------|------------------------|---------|
| Age (years)                    | 58.9 ± 13                         | 61.6 ± 13.3                   | 0.735   |                        |                        |         |
| Central renal lesion           | 27 (58.7)                         | 77 (47)                      | 0.159   |                        |                        |         |
| Mass size                      | 4.1 ± 1.59                        | 3.9 ± 1.6                    | 0.799   |                        |                        |         |
| <4cm                           | 23 (50)                           | 102 (62.2)                    |         |                        |                        |         |
| >4cm                           | 23 (50)                           | 62 (37.8)                    |         |                        |                        |         |

Table 4. Transfusion rates among different variables in patients undergoing laparoscopic PN. Values in parentheses are percentages; Abbreviations: PBT = Perioperative blood transfusion; RCC = Renal Cell Carcinoma; HA = Hemostatic agents; DVT = deep vein thrombosis; PE = pulmonary embolism. *Angiomyolipoma (AML), Oncocytoma, simple cyst.

| Variable                      | Suture, HA and SURGICEL (n = 46) | Sutures and SURGICEL (n = 164) | P value |
|-------------------------------|----------------------------------|--------------------------------|---------|
| Age (years)                   | 58.9 ± 13                        | 61.6 ± 13.3                    | 0.735   |
| Central renal lesion          | 27 (58.7)                        | 77 (47)                       | 0.159   |
| Mass size                     | 4.1 ± 1.59                       | 3.9 ± 1.6                     | 0.799   |
| <4cm                          | 23 (50)                          | 102 (62.2)                     |         |
| >4cm                          | 23 (50)                          | 62 (37.8)                      |         |

Pathology

| Pathology                     | Suture, HA and SURGICEL (n = 46) | Sutures and SURGEL (n = 164) | P value |
|-------------------------------|----------------------------------|-------------------------------|---------|
| Malignant (RCC)               | 32 (69.6)                        | 128 (78)                      | 0.16    |
| Non-malignant*                | 14 (30.4)                        | 36 (22)                       | 0.005   |
| Renal vascular clamping       |                                   |                               |         |
| Yes                           | 42 (91.3)                        | 47 (28.7)                     |         |
| No                            | 4 (8.7)                          | 117 (71.3)                    |         |
| Ischemia Time (min)           | 18.8 ± 7.5                       | 18.2 ± 7.96                   | 0.813   |
| PBT                           | 13 (28.3)                        | 33 (20.1)                     | 0.238   |
| Leak                          | 1 (2.2)                          | 6 (3.7)                       | 0.620   |

Table 5. Transfusion rates among different variables in patients undergoing open PN. Values in parentheses are percentages; Abbreviations: PBT = Perioperative blood transfusion; RCC = Renal Cell Carcinoma; HA = Hemostatic agents; DVT = deep vein thrombosis; PE = pulmonary embolism. *Angiomyolipoma (AML), Oncocytoma, simple cyst.

SURGICEL did not reduce the rate of complications, including urinary leak or the need for PBT. Moreover, since vascular clamping was previously associated with decreased hemorrhagic complications, and specifically lower PBT rate\(^{12}\), we further analyzed the theoretical advantage of HA to sutures and SURGICEL in patients in which
renal artery clamping was not performed. Such analysis revealed no advantage with the use of HA, both in comparison to sutures alone or sutures combined with SURGICEL.

In regards to surgical approach, most studies thus far have examined the beneficial effects of these agents, specifically in LPN. In the current study, we included also patients undergoing OPN. LPN is technically challenging and requires advanced laparoscopic skills. Hence, the laparoscopic approach is often reserved for small, peripheral, exophytic tumors. In this study, patients operated via an open approach had significantly larger, centrally located tumors and significantly lower rate of vascular clamping (data not shown). Interestingly, even in this "high risk" subgroup of patients, the addition of HAs over a bolster of SURGICEL did not reveal even a slight advantage in any of the examined outcomes.

In addition to the main theoretical benefit of HAs in minimizing postoperative bleeding and decreasing the rate of postoperative blood transfusion, HAs were also suggested to limit warm ischemia time by decreasing the amount of intracorporeal suturing and in some cases potentially promote collecting system healing and reduce postoperative urinary leak. The lack of advantages in any of these aspects in the current cohort, raises the question as to whether HAs should still be used in patients undergoing PN. Supporting these conclusions, a recent study by Cohen et al., analyzed the use of a specific type of HAs, Fibrin sealants, during robot-assisted partial nephrectomy (RAPN). Cohen and colleagues demonstrated that the addition of Fibrin glue to hematicostatic suture closure does not decrease the rate of complications, blood loss, or hospital stay. Furthermore, no impact was seen on operative time, ischemia time, or other negative outcomes. Consequently, the authors suggested that omitting these agents during RAPN could be safe and cost-effective. The absolute cost per case may vary between $100–$500, depending on the agent used. At high capacity centers where PNs are routinely performed, the overall cost can be significant. Taking the economic burden into consideration, along with the lack of proven benefits, lead us to the conclusion that the use of HAs, on the whole, is unnecessary in PN patients. We believe that if hemostasis is done well with stitches alone, there is no need for additional adhesive agents. The lack of standardized indications for using HAs vs sutures alone represents some weakness in our study design. However, we believe that this weakness is partly overcome by the fact that all operations were performed in the same surgical environment (four surgeons operating in one medical center) and thus it is reasonable to assume that the decision of using HAs was derived from similar clinical judgment and service routines. Prospective trials would be helpful in interpreting the practicality of these agents.

Limitations of this study include the sample size and the inherent bias associated with its retrospective design. Moreover, the lack of definitive indications for the use of HAs represent some weakness in our study design. However, we believe that this flaw is partly overcome by the fact that all operations were performed in the same surgical environment, a high-volume tertiary care institute and thus it is reasonable to assume that the decision on using HAs was derived from similar clinical judgment and service routines.

Conclusions

In the current study, there was no difference in complication rates using HAs compared with those without. The use of HAs during open and laparoscopic PN does not impact negative outcomes. A proper suture renorrhaphy during partial nephrectomy may be enough to prevent hemorrhagic complications and urine leak. Further study is necessary to support these findings.

References

1. Uzzo, R. G. & Novick, A. C. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 166(1), 6–18 (2001).
2. Aron, M. & Gill, I. S. Minimally invasive nephron-sparing surgery (MNSS) for renal tumours part I: laparoscopic partial nephrectomy. Eur Urol. 51(2), 337–346 (2007).
3. Aron, M. & Turna, B. Laparoscopic partial nephrectomy: Newer trends. Indian J Urol. 25(4), 516–522 (2009).
4. Jung, S., Min, G. E., Chung, B. I. & Jeon, S. H. Risk factors for postoperative hemorrhage after partial nephrectomy. Korean J Urol. 55(1), 17–22 (2014).
5. Bernard, A. C., Davenport, D. L., Chang, P. K., Vaughan, T. B. & Zwischenberger, J. B. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg. 208(5), 931–937 (2009).
6. Linder, B. J., Frank, L., Cheville, J. C. et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 63(5), 839–845 (2013).
7. Tartter, P. I. Blood transfusion and infectious complications following colorectal cancer surgery. Br J Surg. 75(8), 789–792 (1988).
8. Pruthi, R. S., Chum, J. & Richman, M. The use of a fibrin tissue sealant during laparoscopic partial nephrectomy. BJU Int. 93(6), 813–817 (2004).
9. Richter, F. et al. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). Urology. 61(1), 73–77 (2003).
10. King, C. H., Remzi, M., Marberger, M. & Janetschek, G. Haemostasis in laparoscopy. Eur Urol. 50(5), 948–956 (2006).
11. Gill, I. S., Ramani, A. P., Spaliviero, M. et al. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. Urology. 65(3), 463–466 (2005).
12. Scott, R., Meddings, R. N. & Buckley, J. F. Use of fibrin glue for partial nephrectomy. Urology. 39(6), 589 (1992).
13. Breda, A. et al. Use of haemostatic agents and glues during laparoscopic partial nephrectomy: a multi-institutional survey from the United States and Europe of 1347 cases. Eur Urol. 52(3), 798–803 (2007).
14. Guzzo, T. I. et al. Safety and efficacy of a surgeon-prepared gelatin hemostatic agent compared with FloSeal for hemostasis in laparoscopic partial nephrectomy. J Endourol. 23(2), 279–282 (2009).
15. Cohen, J., Jayram, G., Mullins, J. K., Ball, M. W. & Allaf, M. E. Do fibrin sealants impact negative outcomes after robot-assisted partial nephrectomy? J Endourol. 27(10), 1236–1239 (2013).

Author Contributions

Y.A.-G. Data collection or management, Data analysis, Manuscript writing/editing. Z.D. Manuscript writing/editing. I.K. Manuscript writing/editing. D.E.Z. Manuscript writing/editing. J.R. Protocol/project development, Manuscript writing/editing.
Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Abu-Ghanem, Y. et al. The use of Haemostatic Agents does not impact the rate of hemorrhagic complications in patients undergoing partial nephrectomy for renal masses. *Sci. Rep.* 6, 32376; doi: 10.1038/srep32376 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016